
Aytu BioPharma Announces PREVEnt Trial Start Planned for Late 2022 or Early 2023
The specialty pharmaceutical company, AytuBio Pharma, announced this week that it anticipates the PREVEnt trial will begin in late 2022 or early 2023. This study will be investigating the ability of enzastaurin to reduce the severe complications of vEDS. There are currently no FDA-approved therapies for vEDS. Aytu BioPharma CEO Josh Disbrow writes the following: “Aytu BioPharma remains committed View page